Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With Cancer.
Francisco J Bautista SirventJaime VerduDidier FrappazAlba Rubio-San-SimónXavier PaolettiChristian Michel ZwaanMichela CasanovaLynley V MarshallFernando CarcellerFrançois DozCarole LecinseGilles VassalAndrew D J PearsonPamela R KearnsLucas Morenonull nullPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
This study reports a shift in the paradigm of early drug development for childhood cancers, with more biologically relevant targets evaluated in biomarker-driven trials or in combination with other therapies and with more model-based or randomized designs and a greater focus on fulfilling regulatory requirements. Improvement of trial setup and recruitment could increase the number of patients benefiting from novel agents.
Keyphrases
- phase iii
- papillary thyroid
- phase ii
- young adults
- childhood cancer
- end stage renal disease
- clinical trial
- study protocol
- open label
- squamous cell
- newly diagnosed
- chronic kidney disease
- ejection fraction
- double blind
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- transcription factor
- squamous cell carcinoma
- lymph node metastasis
- emergency department
- electronic health record